Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02508077 | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02919878 | Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer | unknown | Phase 2 | 25 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 13, 2018 |
| clinicaltrials |
| NCT01608464 | Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer | terminated | Phase 2 | 170 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT03599778 | XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma | unknown | Phase 1 / Phase 2 | 52 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT00891878 | Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 12 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT03585673 | Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma(DOSE) | unknown | Phase 2 | 38 | Sung Yong OhOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01580410 | Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix | completed | Phase 2 | 136 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT01352728 | Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib | completed | Phase 2 | 50 | Chinese University of Hong KongOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00906373 | A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver | completed | Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT01834963 | P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma. | unknown | Phase 2 | 66 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | May 18, 2018 | clinicaltrials |
| NCT01285778 | Vectibix for the Treatment of Anal Cancer(VITAL) | completed | Phase 2 | 58 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT01912053 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma(MispheC) | completed | Phase 2 | 41 | Center Eugene MarquisOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03520257 | The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | unknown | Phase 2 | 50 | Guangxi Medical UniversityOTHER | 0 | May 9, 2018 | clinicaltrials |
| NCT03511703 | The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | unknown | Phase 2 | 40 | Guangxi Medical UniversityOTHER | 0 | Apr 30, 2018 | clinicaltrials |
| NCT00142480 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00459108 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | terminated | Phase 2 | 9 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01757171 | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | completed | Phase 2 | 85 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT00938470 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT00878215 | Clinical Application of Image-Guided Liver Surgery | terminated | Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01462513 | L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases(LICC) | completed | Phase 2 | 122 | Prof. Dr. Carl SchimanskiOTHER | 2 | Feb 13, 2018 | clinicaltrials |
| NCT02119676 | Study of Ruxolitinib in Colorectal Cancer Patients | terminated | Phase 2 | 396 | Incyte CorporationINDUSTRY | 8 | Feb 13, 2018 | clinicaltrials |
| NCT02392377 | Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01963325 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02978547 | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma(Metformin 001) | unknown | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01729923 | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer(ADAPT) | terminated | Phase 2 | 27 | University of WashingtonOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02400788 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 179 | Yakult Honsha Co., LTDINDUSTRY | 2 | Jan 16, 2018 | clinicaltrials |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | completed | Phase 2 | 8 | Translational Oncology Research InternationalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00848783 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | terminated | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | terminated | Phase 1 / Phase 2 | 9 | University of MiamiOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01043172 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | completed | Phase 2 | 72 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 3, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Aug 16, 2018source: clinicaltrials